Supplementary figure 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma | Synapse
October 2, 2025Open Access
Supplementary figure 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Key Points
Nrf2 hyperactivation may contribute to radiotherapy resistance in cancer patients.
The study indicates that tobacco carcinogen influences primary tumor growth significantly.
Head and neck squamous cell carcinoma shows suppressed antitumor immunity linked to Nrf2 activity.
Understanding Nrf2's role could help develop better therapeutic strategies against cancer.
Abstract
Primary tumor growth influenced by tobacco carcinogen, BAP